MedTrace Logo

Optimal Volume of Bupivacaine in Adductor Canal Nerve Block

NCT02557386 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2016-10-12

No results posted yet for this study

Summary

To establish adequate volume of levobupivacaine 0.25% in adductor canal nerve block in unilateral cruciate ligament of the knee reconstruction surgery.

Conditions

  • Anesthesia, Local

Interventions

DRUG

Levobupivacaine 5 mL

Levobupivacaine 0.25% 5 mL in adductor canal nerve block

DRUG

Levobupivacaine 10 mL

Levobupivacaine 0.25% 10 mL in adductor canal nerve block

DRUG

Levobupivacaine 15 mL

Levobupivacaine 0.25% 15 mL in adductor canal nerve block

DRUG

Levobupivacaine 20 mL

Levobupivacaine 0.25% 20 mL in adductor canal nerve block

DRUG

Levobupivacaine 25 mL

Levobupivacaine 0.25% 25 mL in adductor canal nerve block

DRUG

Levobupivacaine 30 mL

Levobupivacaine 0.25% 30 mL in adductor canal nerve block

Sponsors & Collaborators

  • Pontificia Universidad Catolica de Chile

    lead OTHER

Principal Investigators

  • Fernando R Altermatt, MD · Associate Professor Ordinary Category

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2016-12-31
Completion
2017-03-31

Countries

  • Chile

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02557386 on ClinicalTrials.gov